Skip to main content
Premium Trial:

Request an Annual Quote

Underwriters Exercise Over-allotment Option on Thermo Fisher's $2.2B Public Offering

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today said that the underwriters of its recently announced $2.2 billion public offering of common stock have exercised their over-allotment option.

The underwriters purchased nearly 3.9 million additional shares of Thermo Fisher's stock at $85.50 per share in exercising the over-allotment option.

The company previously entered into forward sale agreements with affiliates of JP Morgan and Barclays with respect to the 25.7 million shares initially offered for sale. Thermo Fisher has also entered into additional forward sale agreements with respect to the 3.9 million shares exercised in the over-allotment option.

The affiliates of JP Morgan and Barclays are now expected to borrow from third parties and sell to the public through the underwriters a total of about 29.6 million shares of common stock in the offering, Thermo Fisher said.

Net proceeds from the offering will be used to fund a portion of the $13.6 billion acquisition of Life Technologies, anticipated to be completed in early 2014. The common stock offering is expected to close on or about June 12.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.